Wednesday, December 04, 2019 10:26:44 PM
That seemed to refer to this, from the text:
"Most glaring was the analyst’s model projecting a course of treatment for Galera’s GC4419 at $15,400 (net). The price point is viewed as in-line with other supportive care treatments.
We conservatively modeled our Brilacidin Oral Rinse pricing at $5,000 for a course of treatment, leaving plenty of room for upward adjustment while providing the opportunity for a decisive pricing advantage."
I can point to the analysts support for that $15,400 cost number for Galera:
"We assume a course of therapy consists of 35 doses, administered over seven weeks, at a gross price of $550/dose, or $15,400 per course of therapy, net of applicable discounts and rebates (we assume 20%)."
So one IV infusion a day for 5 days a week at $550/infusion.
What I'm having trouble determining are the details of the Brilacidin Oral Rinse pricing for a full course at $5,000. Do you know where I can find them?
In the Phase 2 study:
"Patients will use an oral rinse 3 times daily for up to seven weeks during chemoradiation for head and neck cancer."
Is that the same rate of dosing that is reflected in the $5,000 course? 3/day for 7 5 day weeks is about $48/dose.
I couldn't find that anywhere, including here:
http://www.ipharminc.com/press-release/2019/11/13/innovation-pharmaceuticals-oral-cancer-on-the-rise-company-offers-perspectives-on-opportunity-of-brilacidin-for-the-prevention-of-oral-mucositis"
Yes, same dosage frequency: https://clinicaltrials.gov/ct2/show/study/NCT02324335?term=innovation+pharmaceuticals&draw=2&rank=2
"Does the "3X Greater Revenue Potential for Brilacidin Oral Rinse" come from an assumption that there is room for a tripling of the previously unknown price per dose of B-OM."
My thoughts, for your reflection. They(ipix) stated:
We conservatively modeled our Brilacidin Oral Rinse pricing at $5,000 for a course of treatment, leaving plenty of room for upward adjustment while providing the opportunity for a decisive pricing advantage."
I believe it likely boils down to pricing vs costs. If Galera costs are much higher, particularly due to administration costs((iv supervision(over paid healthcare ceo's/underlings), etc, money grubbers)/administration/documentation)), in today's age of fumble, stumble, and trip, it takes not long to escalate things, costs included.
"I need it dumbed down for me. Care to give it a try?"
My thoughts on the matters.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM